Skip to main content
Top
Published in: European Radiology 2/2022

Open Access 01-02-2022 | Hepatocellular Carcinoma | Magnetic Resonance

Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial

Authors: Osman Öcal, Bora Peynircioglu, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alberto Benito, Kerstin Schütte, Antonio Gasbarrini, Ricarda Seidensticker, Moritz Wildgruber, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max Seidensticker

Published in: European Radiology | Issue 2/2022

Login to get access

Abstract

Objectives

To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study.

Methods

A total of 359 patients who underwent gadoxetic acid–enhanced MRI using a standardized protocol with various scanners within a prospective multicenter phase II trial (SORAMIC) were evaluated. The correlation between liver enhancement on hepatobiliary phase normalized to the spleen (liver-to-spleen ratio, LSR) and biochemical laboratory parameters, clinical findings related to liver functions, liver function grading systems (Child-Pugh and Albumin-Bilirubin [ALBI]), and scanner characteristics were analyzed using uni- and multivariate analyses.

Results

There was a significant positive correlation between LSR and albumin (rho = 0.193; p < 0.001), platelet counts (rho = 0.148; p = 0.004), and sodium (rho = 0.161; p = 0.002); and a negative correlation between LSR and total bilirubin (rho = −0.215; p < 0.001) and AST (rho = −0.191; p < 0.001). Multivariate analysis confirmed independent significance for each of albumin (p = 0.022), total bilirubin (p = 0.045), AST (p = 0.031), platelet counts (p = 0.012), and sodium (p = 0.006). The presence of ascites (1.47 vs. 1.69, p < 0.001) and varices (1.55 vs. 1.69, p = 0.006) was related to significantly lower LSR. Similarly, patients with ALBI grade 1 had significantly higher LSR than patients with grade 2 (1.74 ± 0.447 vs. 1.56 ± 0.408, p < 0.001); and Child-Pugh A patients had a significantly higher LSR than Child-Pugh B (1.67 ± 0.44 vs. 1.49 ± 0.33, p = 0.021). Also, LSR was negatively correlated with MELD-Na scores (rho = −0.137; p = 0.013). However, one scanner brand was significantly associated with lower LSR (p < 0.001).

Conclusions

The liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI is correlated with biomarkers of liver functions in a multicenter cohort. However, this correlation shows variations between scanner brands.

Key Points

• The correlation between liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI and liver function is consistent in a multicenter-multivendor cohort.
• Signal intensity–based indices (liver-to-spleen ratio) can be used as an imaging biomarker of liver function.
• However, absolute values might change between vendors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Motosugi U, Ichikawa T, Tominaga L et al (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623–2629PubMedCrossRef Motosugi U, Ichikawa T, Tominaga L et al (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623–2629PubMedCrossRef
2.
go back to reference Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C (2020) The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol 30:6593–6602PubMedCrossRef Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C (2020) The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol 30:6593–6602PubMedCrossRef
3.
go back to reference Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M (2016) Magnetic Resonance imaging of liver metastasis. Semin Ultrasound CT MR 37:533–548PubMedCrossRef Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M (2016) Magnetic Resonance imaging of liver metastasis. Semin Ultrasound CT MR 37:533–548PubMedCrossRef
5.
go back to reference Takatsu Y, Kobayashi S, Miyati T, Shiozaki T (2016) Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system. Eur J Radiol 85:2206–2210PubMedCrossRef Takatsu Y, Kobayashi S, Miyati T, Shiozaki T (2016) Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system. Eur J Radiol 85:2206–2210PubMedCrossRef
6.
go back to reference Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600–6610PubMedPubMedCentralCrossRef Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600–6610PubMedPubMedCentralCrossRef
7.
go back to reference Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042–1046PubMedCrossRef Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042–1046PubMedCrossRef
8.
go back to reference Kim HY, Choi JY, Park CH et al (2013) Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis. J Gastroenterol 48:1180–1187PubMedCrossRef Kim HY, Choi JY, Park CH et al (2013) Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis. J Gastroenterol 48:1180–1187PubMedCrossRef
9.
go back to reference Matsushima S, Sato Y, Yamaura H et al (2014) Visualization of liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase imaging. Magn Reson Imaging 32:654–659PubMedCrossRef Matsushima S, Sato Y, Yamaura H et al (2014) Visualization of liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase imaging. Magn Reson Imaging 32:654–659PubMedCrossRef
10.
go back to reference Matoori S, Froehlich JM, Breitenstein S et al (2019) Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 29:5813–5822PubMedCrossRef Matoori S, Froehlich JM, Breitenstein S et al (2019) Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 29:5813–5822PubMedCrossRef
11.
go back to reference Higaki A, Tamada T, Sone T et al (2012) Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging 30:689–693PubMedCrossRef Higaki A, Tamada T, Sone T et al (2012) Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging 30:689–693PubMedCrossRef
12.
go back to reference Onoda M, Hyodo T, Murakami T et al (2015) Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: comparison of three methods. Eur J Radiol 84:339–345PubMedCrossRef Onoda M, Hyodo T, Murakami T et al (2015) Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: comparison of three methods. Eur J Radiol 84:339–345PubMedCrossRef
13.
go back to reference Okada M, Murakami T, Kuwatsuru R et al (2016) Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 281:474–483PubMedCrossRef Okada M, Murakami T, Kuwatsuru R et al (2016) Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 281:474–483PubMedCrossRef
14.
go back to reference Theilig D, Elkilany A, Schmelzle M et al (2019) Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. Abdom Radiol (NY) 44:2759–2768CrossRef Theilig D, Elkilany A, Schmelzle M et al (2019) Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. Abdom Radiol (NY) 44:2759–2768CrossRef
15.
go back to reference Ricke J, Klümpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164–1174PubMedCrossRef Ricke J, Klümpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164–1174PubMedCrossRef
16.
go back to reference Wang Y, Zhong J, Su Z et al (2016) Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg 103:725–734PubMedCrossRef Wang Y, Zhong J, Su Z et al (2016) Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg 103:725–734PubMedCrossRef
17.
go back to reference Londoño M-C, Cárdenas A, Guevara M et al (2007) MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 56:1283–1290PubMedPubMedCentralCrossRef Londoño M-C, Cárdenas A, Guevara M et al (2007) MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 56:1283–1290PubMedPubMedCentralCrossRef
18.
go back to reference Liu PH, Hsu CY, Hsia CY et al (2017) ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 32:879–886PubMedCrossRef Liu PH, Hsu CY, Hsia CY et al (2017) ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 32:879–886PubMedCrossRef
19.
go back to reference Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33:550PubMedCrossRef Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33:550PubMedCrossRef
20.
go back to reference Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol 42:S100–S107PubMedCrossRef Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol 42:S100–S107PubMedCrossRef
21.
go back to reference Biggins SW, Kim WR, Terrault NA et al (2006) Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130:1652–1660PubMedCrossRef Biggins SW, Kim WR, Terrault NA et al (2006) Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130:1652–1660PubMedCrossRef
22.
go back to reference Albers I, Hartmann H, Bircher J, Creutzfeldt W (1989) Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 24:269–276PubMedCrossRef Albers I, Hartmann H, Bircher J, Creutzfeldt W (1989) Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 24:269–276PubMedCrossRef
23.
go back to reference Tsuboyama T, Onishi H, Kim T et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824–833PubMedCrossRef Tsuboyama T, Onishi H, Kim T et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824–833PubMedCrossRef
24.
go back to reference Morin C, Drolet S, Daigle C et al (2020) Additional value of gadoxetic acid-enhanced MRI to conventional extracellular gadolinium-enhanced MRI for the surgical management of colorectal and neuroendocrine liver metastases. HPB (Oxford) 22:710–715CrossRef Morin C, Drolet S, Daigle C et al (2020) Additional value of gadoxetic acid-enhanced MRI to conventional extracellular gadolinium-enhanced MRI for the surgical management of colorectal and neuroendocrine liver metastases. HPB (Oxford) 22:710–715CrossRef
25.
go back to reference Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J et al (2019) The added diagnostic value of complementary gadoxetic acid-enhanced MRI to (18)F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 19:73PubMedPubMedCentralCrossRef Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J et al (2019) The added diagnostic value of complementary gadoxetic acid-enhanced MRI to (18)F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 19:73PubMedPubMedCentralCrossRef
26.
go back to reference Verloh N, Probst U, Utpatel K et al (2019) Influence of hepatic fibrosis and inflammation: correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 14:e0215752PubMedPubMedCentralCrossRef Verloh N, Probst U, Utpatel K et al (2019) Influence of hepatic fibrosis and inflammation: correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 14:e0215752PubMedPubMedCentralCrossRef
27.
go back to reference Leonhardt M, Keiser M, Oswald S et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028PubMedCrossRef Leonhardt M, Keiser M, Oswald S et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028PubMedCrossRef
28.
go back to reference Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674–682PubMedCrossRef Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674–682PubMedCrossRef
29.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMedCrossRef
30.
go back to reference Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS (2016) Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 34:1787–1794PubMedPubMedCentralCrossRef Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS (2016) Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 34:1787–1794PubMedPubMedCentralCrossRef
31.
go back to reference Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238–iv255PubMedCrossRef Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238–iv255PubMedCrossRef
32.
go back to reference Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMedCrossRef Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMedCrossRef
33.
go back to reference Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef
34.
go back to reference Investigators CLIP (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751–755CrossRef Investigators CLIP (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751–755CrossRef
35.
go back to reference Jin YJ, Lee SH, Cho SG et al (2016) Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1349–1356PubMedCrossRef Jin YJ, Lee SH, Cho SG et al (2016) Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1349–1356PubMedCrossRef
36.
go back to reference Tsujita Y, Sofue K, Komatsu S et al (2020) Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion. Eur J Radiol 130:109189PubMedCrossRef Tsujita Y, Sofue K, Komatsu S et al (2020) Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion. Eur J Radiol 130:109189PubMedCrossRef
37.
go back to reference Araki K, Harimoto N, Yamanaka T et al (2020) Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus. Surg Today 50:1496–1506PubMedCrossRef Araki K, Harimoto N, Yamanaka T et al (2020) Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus. Surg Today 50:1496–1506PubMedCrossRef
38.
go back to reference Kim DK, Choi JI, Choi MH et al (2018) Prediction of posthepatectomy liver failure: MRI with hepatocyte-specific contrast agent versus indocyanine green clearance test. AJR Am J Roentgenol 211:580–587PubMedCrossRef Kim DK, Choi JI, Choi MH et al (2018) Prediction of posthepatectomy liver failure: MRI with hepatocyte-specific contrast agent versus indocyanine green clearance test. AJR Am J Roentgenol 211:580–587PubMedCrossRef
39.
go back to reference Kim AY, Sinn DH, Jeong WK et al (2018) Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol 68:1144–1152PubMedCrossRef Kim AY, Sinn DH, Jeong WK et al (2018) Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol 68:1144–1152PubMedCrossRef
40.
go back to reference Zech CJ, Ba-Ssalamah A, Berg T et al (2020) Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 30:370–382PubMedCrossRef Zech CJ, Ba-Ssalamah A, Berg T et al (2020) Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 30:370–382PubMedCrossRef
41.
go back to reference Poetter-Lang S, Bastati N, Messner A et al (2020) Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 45:3532–3544CrossRef Poetter-Lang S, Bastati N, Messner A et al (2020) Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 45:3532–3544CrossRef
Metadata
Title
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
Authors
Osman Öcal
Bora Peynircioglu
Christian Loewe
Otto van Delden
Vincent Vandecaveye
Bernhard Gebauer
Christoph J. Zech
Christian Sengel
Irene Bargellini
Roberto Iezzi
Alberto Benito
Kerstin Schütte
Antonio Gasbarrini
Ricarda Seidensticker
Moritz Wildgruber
Maciej Pech
Peter Malfertheiner
Jens Ricke
Max Seidensticker
Publication date
01-02-2022
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 2/2022
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-08218-9

Other articles of this Issue 2/2022

European Radiology 2/2022 Go to the issue